Topical Cyclosporine A cationic ophthalmic emulsion effective treatment option for vernal keratoconjunctivitis in kids

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-08-25 14:30 GMT   |   Update On 2023-08-26 10:52 GMT
Advertisement

Topical Cyclosporine A cationic ophthalmic emulsion effective treatment option for vernal keratoconjunctivitis in kids suggests a new study published in the Eye

Cyclosporine A cationic ophthalmic emulsion (CsA CE) was evaluated in paediatric and adolescent patients with vernal keratoconjunctivitis (VKC) in the NOVATIVE (NCT00328653) and VEKTIS (NCT01751126) trials. The similarity of these studies permitted pooled assessment of the effect of Cyclosporine A cationic ophthalmic emulsion on corneal damage as well as safety and tolerability.

Advertisement

Subjects/Methods

Pooled outcomes were assessed for the first 28 days of treatment. In NOVATIVE, 118 patients were randomised to 4 times daily (QID) Cyclosporine A cationic ophthalmic emulsion 0.05%, 0.1%, or vehicle eye drops. In VEKTIS, 169 patients were randomised to Cyclosporine A cationic ophthalmic emulsion 0.1% QID or twice daily (BID) or vehicle. For these analyses, treatment groups comprised: (1) pooled CsA CE 0.1% QID arms (high-dose; n = 96); (2) pooled CsA CE 0.05% QID arm from NOVATIVE and Cyclosporine A cationic ophthalmic emulsion 0.1% BID data from VEKTIS (low-dose; n = 93); and (3) pooled vehicle QID arms (vehicle; n = 98).

Results

Changes from baseline to day 28 (mean ± standard deviation) in corneal fluorescein staining (CFS) scores for Cyclosporine A cationic ophthalmic emulsion high-dose, low-dose, and vehicle groups were −1.6 ± 1.47 (95% CI: −0.9, −0.1; p = 0.0124 vs vehicle), −1.7 ± 1.39 (95% CI: −1.1, −0.3; p = 0.0015 vs vehicle), and −1.0 ± 1.55, respectively. Adverse events (AEs) of any type were reported in 37.5%, 34.4%, and 37.8% of the high-dose, low-dose, and vehicle groups, respectively. Most were mild or moderate in severity.

Cyclosporine A cationic ophthalmic emulsion significantly decreased corneal damage and was safe and well tolerated in patients with VKC. These data support Cyclosporine A cationic ophthalmic emulsion as a treatment option for the management of VKC.

Reference:

Leonardi, A., Doan, S., Aragona, P. et al. Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials. Eye 37, 2320–2326 (2023). https://doi.org/10.1038/s41433-022-02342-6

Tags:    
Article Source : Eye

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News